Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Exelixis Phase 3 STELLAR-303: Zanzalintinib Plus Atezolizumab Extends Survival To 10.9 Months In Metastatic Colorectal Cancer

Author: Benzinga Newsdesk | October 20, 2025 01:45am

– Zanzalintinib in combination with atezolizumab improved median overall survival to 10.9 months versus 9.4 months with regorafenib, and significantly reduced the risk of death by 20% in the intention-to-treat population –

– Exelixis plans to complete its first new drug application submission for zanzalintinib in the U.S. in 2025 –

Posted In: EXEL


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist